Amylin for Diagnosis of Gestational Diabetes Mellitus and Its Association with Advers Obstetric-Neonatal Outcomes

Aim:The aim of the study was to measure serum amylin levels in pregnant women who applied for oral glucose tolerance test(OGTT) between 24-28 weeks,to compare the diagnostic use of amylin in pregnant women with and without a diagnosis of gestational diabetes mellitus(GDM),and to evaluate the relationship between amylin values and obstetric-neonatal outcomes. Material and Methods:The study includes 86 patients selected among 430 pregnant women who applied to the antenatal outpatient clinic for OGTT. 43 of the pregnants whose 50-gr OGTT results were within normal limits; 43 pregnant women who underwent 100-gr OGTT test because their 50-gr OGTT was above 140 mg/dl and diagnosed with GDM because 2 values were defective were determined as the study group.Serum amylin levels were evaluated by matching the control and study groups according to body mass index(BMI). Results:In the study,serum amylin levels were found to be 73.7 in the GDM group and 76.1 in the control group, and there was no significance between the groups(p>0.05). Amylin levels were negatively correlated with age,BMI,gravida,parity in the GDM group,and positively correlated with weight gained and gestational week.There was no statistically significant difference between the groups in terms of obstetric (birth week, birth weight,delivery type,birth trauma) and newborn(NEDCU need) outcomes(p>0.05). Conclusion: Serum amylin concentrations measured before the OGTT do not have a predictive value for the diagnosis of GDM, and serum amylin levels do not predict adverse obstetric and neonatal outcomes.